Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain

1. Cedillo, S.
2. González-Domínguez, A.
3. Ivanova-Markova, Y.
4. López López, R.
5. López-Tarruella Cobo, S.
6. Peña Pedrosa, J.A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1007/S41669-024-00518-2 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus